Doxorubicin (Adriamycin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 1996-06-21: EURD

History of changes in PMDA indication

  • 2014-12-18: Revised indication and a new dosage for the relief of symptoms of malignant lymphoma.

Also known as

  • Code name: FI-106
  • Generic names: ADM, doxorubicin hydrochloride, hydroxydaunorubicin
  • Brand names:
Adriablastina Adriacept Adriacin Adriamycin Adriamycine Adriblastin Adriblastina Adriblastine
Adricept Adricin Adrim Adrimedac Adrosal Antraciclin Biorrub Biorubina
Cadria Carcinocin Cloridrato DE Doxorrubicina Colhidrol Deldoxin Dicladox Dobicin Dobixin
Doxo Doxobin Doxo Cell Doxocris Doxokebir Doxolem Doxonolver Doxor
Doxorrubicina Doxoruben Doxorubicina Doxorubicine Doxorubicinum Doxorubin Doxotec Doxtie
Duxocin Evacet Farmiblastina Fauldoxo Flavicina Ifadox Kemodoxa Lyphidox
Nagun Neoxane Nuaze Oncodria Onkodox Onkostatil Pallagicin Ranxas
Rastocin Ribodoxo Roxorin Rubex Varidoxo Zodox


  1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42. link to original article PubMed